AstraZeneca to Recover Global Rights to Brazikumab From Allergan

AstraZeneca said Monday that it will take back the global rights to brazikumab after ending a license deal with Allergan PLC.
AstraZeneca said Allergen will fund the costs of developing brazikumab, which is used for Crohn’s disease and ulcerative colitis.
The transaction is expected to complete in the first quarter of this year, subject to regulatory approvals associated with AbbVie proposed acquisition of Allergan, AstraZeneca said.
https://www.marketscreener.com/ASTRAZENECA-4000930/news/AstraZeneca-to-Recover-Global-Rights-to-Brazikumab-From-Allergan-29894242/